Statera Biopharma, Inc. financial data

Symbol
STAB on OTC
Industry
Pharmaceutical Preparations
Location
2537 Research Boulevard, Suite 201, Fort Collins, CO
State of incorporation
DE
Fiscal year end
December 31
Former names
Cytocom, Inc. (to 8/17/2021), CLEVELAND BIOLABS INC (to 7/28/2021)
Latest financial report
10-Q - Q3 2022 - Nov 14, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 12.4 %
Debt-to-equity -385 % -1268%
Return On Equity 1.75K %
Return On Assets -602 % -539%
Operating Margin -2.39K % +98.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.7M shares +58.1%
Common Stock, Shares, Outstanding 50.7M shares +58.1%
Common Stock, Value, Issued 254K USD +58.1%
Weighted Average Number of Shares Outstanding, Basic 50.2M shares +85.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.69M USD +21312%
Research and Development Expense 10M USD +47.8%
Selling and Marketing Expense 123K USD -42.6%
General and Administrative Expense 13.1M USD -25.6%
Operating Income (Loss) -88.2M USD -261%
Nonoperating Income (Expense) -3.66M USD +34.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -91.8M USD -205%
Earnings Per Share, Basic -2.28 USD/shares +85.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 506K USD -94.5%
Accounts Receivable, after Allowance for Credit Loss, Current 183K USD +27.1%
Other Assets, Current 248K USD -76.2%
Assets, Current 1.21M USD -90.9%
Property, Plant and Equipment, Net 106K USD -10.7%
Operating Lease, Right-of-Use Asset 914K USD +8.76%
Intangible Assets, Net (Excluding Goodwill) 1.24M USD -21.3%
Goodwill 9.27M USD -88%
Assets 12.7M USD -87%
Accounts Payable, Current 8.13M USD +155%
Employee-related Liabilities, Current 2.89M USD +2037%
Contract with Customer, Liability, Current 387K USD -23.5%
Liabilities, Current 22.2M USD +118%
Operating Lease, Liability, Noncurrent 686K USD -6.95%
Liabilities 22.9M USD -3.88%
Accumulated Other Comprehensive Income (Loss), Net of Tax 53.7K USD
Retained Earnings (Accumulated Deficit) -144M USD -176%
Stockholders' Equity Attributable to Parent -10.2M USD -114%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -10.2M USD -114%
Liabilities and Equity 12.7M USD -87%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.76M USD -45.1%
Net Cash Provided by (Used in) Financing Activities -2.9M USD -234%
Net Cash Provided by (Used in) Investing Activities -6.45K USD -37.8%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 50.7M shares +58.1%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.69M USD -1414%
Interest Paid, Excluding Capitalized Interest, Operating Activities 540K USD
Operating Lease, Liability 1.01M USD +7.92%
Depreciation 6.52K USD +723%
Payments to Acquire Property, Plant, and Equipment 6.45K USD +37.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -91.8M USD -206%
Lessee, Operating Lease, Liability, to be Paid 1.4M USD +1.69%
Operating Lease, Liability, Current 324K USD +63.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 265K USD +1.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 438K USD +46%
Operating Lease, Weighted Average Discount Rate, Percent 0.16 pure +22.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 392K USD -11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 174K USD +5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 182K USD +5%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 114K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%